Takeda Pharmaceuticals Korea seeks DPP-4 market through ‘Nesina’
(Yakup Shinmoon)
On Jan 17, Takeda Pharmaceuticals Korea held a large-scale symposium and press conference to announce the launch of type 2 diabetes treatment 'Nesina tablet' (ingredient: alogliptin benzoate).
Nesina tablet is a DPP-4 inhibitor for the treatment of type 2 diabetes. Takeda...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
